How long should you keep pts on TCZ for GCA after remission has been achieved? @RheumNow #eular2020

#EULAR2020 Dr. Kimme Hyrich reviews the EULAR #COVID19 Registry "Most individuals with rheumatic diseases receiving immunosuppressive therapies recover from COVID19" @rheumnow https://t.co/EdVLUMyHhF

SELECT-PSA-2 results: UPA15 & UPA30 showed improvement across PsA domains vs PBO through Wk 24. No new safety signals were identified. Check out abstract #OP0223 for the MDA/ACR50/ACR70 responses. #EULAR2020 @RheumNow https://t.co/UAx2tkKSZI

Study out of Switzerland finds lower response rates to TNFi in women with nr-axSpA vs men. Poster #THU0383 #EULAR2020 @RheumNow https://t.co/uWNqwqamQM https://t.co/pgnhCaw9f6

• E-CONGRESS

This Spanish study of 255 SpA pts found that acute unilateral anterior uveitis was the most common pattern, primarily in HLA B27+. NO difference in incidence between SEC and TNFi treated pts. #EULAR2020 @RheumNow Poster #THU0388 https://t.co/OMfG8atfE4

nr-axSpA pts with active inflammation improved with IXE. Drug efficacy did not change in pts with elevated CRP or sacroiliitis or both. #EULAR2020 @RheumNow poster #THU0395 https://t.co/ap6Wy2eNBL https://t.co/zLoNHuSVV5

• E-CONGRESS

COAST-V and COAST-X trial results: Both TNFi experienced and naive AS pts had better work productivity compared to PBO. #EULAR2020 @RheumNow poster #THU0396 https://t.co/UPDpLqCSkG https://t.co/UTLzxxTG8K

• E-CONGRESS

10 ReA pt study out of India reviewing ETN-b found that all pts (previously on ETN) responded to biosimilar med without new safety signals. Further details are here on abstract #AB0632 https://t.co/lRA2IDvU4H #EULAR2020 @RheumNow https://t.co/QyhwBzBBH3

• EULAR Abstract Archive

Interesting observation: obese patients seem to respond better to etanercept than to mAb TNFi @RheumNow https://t.co/WrjwE4jUNI

• https://twitter.com/pkiely500/status/1268871993539072001

Big one from plenary, new option in ANCA-associated vasculitis: avacopan (anti-C5a) vs prednisolone in patients receiving CYC/RTX: non-inf at 26w, superior at 52w in the phase III ADVOCATE trial with reduction in steroid toxicity Merkel, Jayne et al OP0011 #EULAR2020 @RheumNow

#eular2020 #op0302 Ianalumab (VAY736) dual action BAFFreceptor inhibitor/B cell depletion meets primary end point in p2b for pSS: EESDAI⬇️1.92 pts over PBO at wk24. Dis not meet 2ry endpoint ESSPRI&FACIT-F. Good side effect profile w/mild inj site reactions mostly @RheumNow https://t.co/9qsfUNho9h

You might think that steroid exposure in PMR patients wouldn't lead to new comorbidities. These data beg to differ. New steroid-related comorbidities ++ across domains vs matched controls in real-world US claims data. We need steroid-sparing in PMR. OP0271 #EULAR2020 @RheumNow https://t.co/mSzWcJSpfV

Does TCZ actually fix GCA? @nihrheumatology cohort w serial PET/CT q6m: FDG uptake (PETVAS) reduces longitudinally over 2y but does not normalise, w rebound on TCZ cessation Ongoing reductions in year 2? GCA doesn't sleep. @KQuinnRheum @petercgrayson OP0144 #EULAR2020 @RheumNow https://t.co/aczQbONcNc

Our study shows that HCQ retinopathy virtually never occurs in first 5 yrs, SLE has more risk than other diseases such as RA and chloroquine has a far higher risk of retinal toxicity OP0333 #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/ZzRy3po4yw

• https://twitter.com/kdao2011/status/1268532437275025409

#EULAR2020 OP0167 Results are finally in!! MMF can be safely w/drawn in quiescent SLE: prospect RCT (nonblinded) 102 pts. MMF tapered over 12 weeks, f/u 60 weeks; no sig diff for flares in pts who stopped MMF vs. maintained; pts who cont MMF had ⬆️ minor infections. @rheumnow https://t.co/bOnuEBLis9